Processes of Change Related to Smoking Behavior Among Cancer Patients

Schnoll, Robert A.; Malstrom, Michael; James, Calvin; Rothman, Randi L.; Miller, Suzanne M.; Ridge, John A.; Movsas, Benjamin; Langer, Corey J.; Unger, Michael; Goldberg, Melvyn

doi:10.1046/j.1523-5394.2002.101009.x

Cited by 15 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ns denote number of studies in the analysis for Full Sample/Current Smokers at Cancer Diagnosis. Full Sample: 0-3 includes data from (4, 10, 34, 40, 42, 54, 63, 73, 80, 84, 110, 127, 132, 134, 135, 143, 145, 147, 154); 4-6 includes data from (51, 131, 153); 7-11 includes data from (49, 133); 12-59 includes data from (59, 79, 85, 86, 88, 91, 97, 100, 141, 152); 60+ includes data from (67, 70, 128); and Mixed includes data from (5, 29-31, 46, 52, 56, 62, 69, 90, 94, 95, 98, 103, 112, 115, 120-122, 125, 126, 130, 138). Current Smokers at Cancer Diagnosis: 0-3 includes data from (4, 34, 39, 40, 80, 82, 84, 110, 143, 149); 4-6 includes data from (76, 153); 7-11 includes data from (123); 12-59 includes data from (36, 97); 60+ includes data from (128); and Mixed includes data from (5, 35, 44, 46, 56, 112, 115, 125, 129, 138).…”

Section: Figurementioning

confidence: 99%

Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research

Burris

Studts

DeRosa

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Tobacco use after cancer diagnosis is associated with adverse cancer outcomes, yet reliable prevalence estimates for this behavior are lacking. We conducted a systematic literature review of the prevalence of current tobacco use among individuals with a history of lung or head/neck cancer (CRD #42012002625). An extensive search of electronic databases (MEDLINE, EMBASE, Cochrane Library, CINAHL, PsycINFO, Web of Science) identified 7,777 potentially relevant papers published between 1980 and 2014, and 131 of these yielded pertinent information. Aggregating results across heterogeneous study designs and diverse patient samples, the overall mean prevalence rate of current tobacco use (mostly cigarette smoking) was 33.0% (median=31.0%). Among current tobacco users at cancer diagnosis, the mean prevalence rate of current tobacco use (mostly cigarette smoking) was 53.8% (median=50.3%). In many cases, an operational definition of “current” tobacco use was absent, and biochemical verification of self-reported smoking status was infrequent. These and other observed methodological limitations in the assessment and reporting of cancer patients’ tobacco use underscore the necessity of uniform tobacco use assessment in future clinical research and cancer care.

show abstract

Section: Figurementioning

confidence: 99%

Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research

Burris

Studts

DeRosa

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Two explanations may be offered. On the one hand, as reported by Irwin (2009) and Schnoll et al (2002), physical symptoms (e.g. fatigue) or emotional barriers (e.g.…”

Section: Discussionmentioning

confidence: 98%

“…Summarily, overcoming cancer-related barriers appears to play an important role in the formation of intention by enhancing the control individuals feel towards their disease (Schnoll et al, 2002). This suggests that among facets of the cancer experience that prevent this population from engaging in and adhering to therapeutic PA, cancer-related barriers are a key construct.…”

Section: Discussionmentioning

confidence: 99%

Barriers Identification as Intervention to Engage Breast Cancer Survivors in Physical Activity

André

Pillaud

Davoust

et al. 2018

Psychosocial Intervention

View full text Add to dashboard Cite

Although scientific evidence supports the role of physical activity (PA) as a safe and effective intervention for improving health-related quality of life (for a review, see Mishra et al., 2012;Irwin, 2009), the majority of cancer survivors do not comply with public health guidelines (Blanchard, Courneya, & Stein, 2008;Lynch et al., 2010), i.e. at least 150 minutes per week of moderate-intensity aerobic PA throughout the week or at least 75 minutes of vigorous-intensity aerobic PA throughout the week, or an equivalent combination of This study was designed to demonstrate the advantage of adding cancer barriers to components of decision-making in the transtheoretical model (TTM). In study 1, questionnaires were completed by 139 breast cancer survivors including decisional balance, cancer-related barriers and stages of readiness. In study 2, efficiency of directly tackling cancer-related barriers through motivational-style conversation was tested in a quasi-experimental design. From study 1, all decisionmaking variables were related to stages of readiness, but cancer-related barriers were the sole predictors of engagement in physical activity. Out of the three groups of study 2, only the group with motivational-style conversation displayed a significant progress for engagement in physical activity. Demonstrating that cancer-related barriers predict stage of change above the effects of the two components of decisional balance provides a validation of positions that put cancer-related barriers as uniquely related to stages of change, and suggests that adding them in decision making variables in TTM's model can provide a genuinely new contribution to the understanding of physical activity adherence. Regarding implication for cancer survivors, these results suggest that in order to stimulate progress in early stages of change, a greater emphasis may be needed on reducing cancer-related barriers. La identificación de barreras como intervención para involucrar a supervivientes de cáncer de mama en actividades físicas R E S U M E NEste estudio fue diseñado para demostrar la ventajas de tener en cuenta las barreras relacionadas con el cáncer en el proceso de toma de decisiones en el modelo transteórico. En el estudio 1 los cuestionarios fueron respondidos por 139 supervivientes de cáncer de mama, en ellos se incluyó el equilibrio decisional, las barreras relacionadas con el cáncer y las etapas de preparación. En el estudio 2 la eficacia de abordar las barreras relacionadas con el cáncer a través de conversaciones de tipo motivacional se puso a prueba con un diseño cuasi-experimental. En el estudio 1 todas las variables de toma de decisiones se relacionaron con las etapas de preparación, pero las barreras relacionadas con el cáncer fueron los únicos predictores de la participación en la actividad física. De los tres grupos del estudio 2, sólo el grupo con conversación de tipo motivacional mostró un progreso significativo para la participación en la actividad física. Demostrar que las barreras relacionadas con el cáncer pre...

show abstract

“…Patients enrolled in a cessation program have a high prevalence of depressive symptoms, low self-confidence about quitting, low perceived risk of health problems, and low perceived benefits from smoking cessation; however, patients characterized by a shorter time since diagnosis, lower tobacco use and nicotine dependence, higher perceived risk of smoking, and higher perceived benefit of quitting were more motivated to quit (76). Other studies have shown that higher rates of smoking cessation were associated with higher levels of counter-conditioning and reinforcement management, lower levels of self-reevaluation, female sex, higher baseline health, lower nicotine dependence, surgical treatment (as opposed to radiotherapy), being non-Caucasian, and being in an “action” stage of change (71, 77, 78). However, lesser readiness to quit, higher nicotine dependence, higher cravings, lower education, younger age of initiation, higher level of pain, and smoking cessation less than 6 months prior to surgery have been associated with higher rates of relapse (75, 79, 80).…”

Section: Tobacco Cessation Treatmentmentioning

confidence: 99%

Tobacco Use in the Oncology Setting: Advancing Clinical Practice and Research

Gritz

Toll

Warren

2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

105

View full text Add to dashboard Cite

While tobacco is a well-established causal agent for many human cancers, less emphasis has been placed on translating this evidence by evaluating the effects of continued tobacco use after a cancer diagnosis. A broad assessment of the effects of continued tobacco use demonstrates that tobacco increases cancer treatment toxicity, recurrence, second primary tumors, and mortality in cancer patients. Few studies report the potential benefits of cessation after a cancer diagnosis, but data suggest improved treatment outcomes in cancer patients who quit smoking. Improving tobacco cessation treatment efficacy and access to cessation support has been sparsely researched in the oncology setting compared with the general population; however, cancer patients are receptive to standard evidence based tobacco cessation guidelines. Several studies demonstrate moderate tobacco cessation success in cancer patients using the general principles of evidence based tobacco cessation support. Several systems level issues and research efforts are needed to standardize tobacco use definitions, increase access to tobacco cessation support, improve tobacco cessation efficacy, understand the time dependent effects of tobacco and cessation on cancer biology, and realize the potential benefits of tobacco cessation for cancer patients.

show abstract

Processes of Change Related to Smoking Behavior Among Cancer Patients

Cited by 15 publications

References 51 publications

Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research

Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research

Barriers Identification as Intervention to Engage Breast Cancer Survivors in Physical Activity

Tobacco Use in the Oncology Setting: Advancing Clinical Practice and Research

Contact Info

Product

Resources

About